Clinical characteristics and outcomes of COVID-19 in patients with autoimmune hepatitis: A population-based matched cohort study

Table 2 Baseline characteristics of patients with autoimmune hepatitis and non-autoimmune hepatitis chronic liver diseases patients with a positive test for severe acute respiratory syndrome coronavirus-2

Variables	Before propensity score matching			After propensity score matching
	AIH (n = 375)	Non-AIH CLD (n = 15790)	P value	AIH (n = 363)	Non-AIH CLD (n = 363)	P value
Age, yr, mean ± SD	53.1 ± 18.5	60.3 ± 12.1	< 0.01	53.9 ± 18.1	54.3 ± 15.5	0.76
Sex, n (%)
Female	267 (71.2)	6517 (41.2)	< 0.01	262 (72.1)	266 (73.2)	0.74
Ethnicity, n (%)
Hispanic or Latino	82 (21.8)	1579 (10)	< 0.01	82 (22.5)	67 (18.4)	0.19
Race, n (%)
White	236 (62.9)	11132 (70.5)	0.02	235 (64.7)	218 (60.1)	0.19
Black or African American	65 (17.3)	2462 (15.5)	0.41	58 (15.9)	72 (19.8)	0.17
Other	66 (17.6)	1824 (11.5)	0.04	62 (17.1)	61 (16.8)	0.92
Nicotine dependence, n (%)	87 (23.2)	1831 (11.5)	< 0.01	89 (24.5)	87 (23.9)	0.94
BMI (kg/m2), mean ± SD	28.9 ± 7.1	30.4 ± 7.48	0.09	29 ± 7.11	28.7 ± 7.79	0.72
Comorbidities, n (%)
Hypertension	165 (44)	11469 (72.6)	< 0.01	161 (44.3)	200 (55.1)	0.03
Ischemic heart diseases	62 (16.5)	5472 (34.6)	< 0.01	59 (16.2)	56 (15.4)	0.76
Heart failure	39 (10.4)	4196 (26.5)	< 0.01	38 (10.4)	48 (13.2)	0.25
Diabetes	74 (19.7)	7882 (49.9)	0.01	74 (20.4)	66 (18.1)	0.45
Chronic lower respiratory diseases	84 (22.4)	5843 (37.0)	< 0.01	82 (22.5)	79 (21.7)	0.79
Cerebrovascular diseases	37 (9.8)	3079 (19.4)	< 0.01	37 (10.1)	39 (10.7)	0.81
CKD of any stage	49 (13.1)	5102 (32.3)	< 0.01	46 (12.6)	55 (15.1)	0.33
Neoplasms	131 (34.9)	8400 (53.1)	< 0.01	124 (34.1)	131 (36.1)	0.59

AIH: Autoimmune hepatitis; CLD: Chronic liver diseases; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2; SD: Standard deviation; BMI: Body mass index; CKD: Chronic kidney disease.